Who we are

We are on a mission to help you to create superior value and optimise healthcare worldwide.

Our experience and expertise across a wide range of therapeutic areas, including orphan and speciality products, has helped us to develop structured methods and approaches to generate solutions for even the toughest pricing and market access challenges. You will get the best open and honest strategic advice as well as practical operational execution from a team that is globally networked with specific expertise across key markets within Europe, USA, Canada, China, and Japan.

Our vision

Inbeeo was founded from a clear bold vision.

We believe in "A world where the value of health technologies is fully realised"

In any given year, there is a $50 billion gap between analysts’ predicted sales for all new life science products launches and their actual sales. At Inbeeo, we believe that alongside scientific challenges, the root cause of this gap is the lack of careful planning for and demonstration of value. This is why we call it “the value gap”.

Our missions

With our vision in mind, we have aligned our services and products to four key mission areas

Asset 1

Help you to price right

All health technologies should be priced according to the value they bring to patients, healthcare systems and society. We have tools and methods to help you to solve that equation.

Asset 2

Help you to understand the data

Understanding inevitably starts with data. We help you collect data and translate this information into insight and action.
Asset 3

Help you to define the strategy

Maximising the value of health technologies requires making the right decisions at the right time. We apply best-in-class strategy development methods tailored to your needs.
Asset 36

Help you to operationalise the value

Even the best strategies will fail without proper execution. We partner with you to translate your asset value and pricing strategy into an operational reality.

Learn more about our services and products.

Asset 10
Asset 10

Our core values

Our core values reflect our growing organisation and how we partner with you to achieve the exceptional results that you are looking for. Our core values are embedded in every interaction and decision we make:
Asset 12
We commit ourselves to deliver your project to the highest standards
Asset 13
We strive to provide you with new and creative solutions to your individual challenges
Asset 3

We never compromise on doing the right thing for our team, partners and wider society

Asset 1
We strive to think ‘outside-the-box’, approaching our partnerships and projects with fresh eyes and an open mindset
Asset 2
We are motivated and inspired by working with you to contribute to the improvement of healthcare worldwide
Asset 8
We grow as individuals and as one team and we are aligned with our partners on achieving growth for their business and for ours

Our commitments to you

Asset 5
We will provide you with a tailored personal service – not a cookie-cutter approach. Each Market Access journey is unique and should be treated as such.
Asset 5
We genuinely care about each project we undertake and hold ourselves accountable to meet our partner’s needs and goals
Asset 5
Each phase of your project is carefully thought through, planned and designed to ensure the best approach is selected to achieve impactful results
Asset 5
We will give you a clear and transparent price for your project
Asset 5
The people that you meet are the people that do the work
Asset 5
We will get it right first time, on time and on budget

The Inbeeo team

Hervé Lilliu

Over the past two decades in the biopharma industry (UCB, Pfizer, IMS), Hervé has been creating value for patients living with severe diseases by supporting the development, reimbursement, and commercialization of truly outstanding products... Prior to founding Inbeeo, Hervé has held diverse senior roles including Chief Market Access and Pricing Officer, Canadian Affiliate President and Global Commercial Lead. An economist by training, Hervé has gained a deep understanding of the global implications of the business having been based successively in Paris, London, Brussels, Toronto and Atlanta.
Read more

Inbeeo team members: Pippa MacNair

Pippa Macnair​

Pippa has extensive experience in delivering strategic market access projects across Europe, the US and Asia, with a particular focus in the orphan space. Specific expertise includes primary payer research, landscape and analogue analyses, value proposition development, and operational market access support. She graduated from the University of St Andrews with a first class degree in Geography, before going on to complete an MSc in Public Health (with distinction) at the London School of Hygiene and Tropical Medicine.
Read more

Inbeeo team members: Jean-Marc Frybourg

Jean-Marc Frybourg​

A graduate of ESCP-Europe and holding a Masters in Market Research and Marketing Strategy, Jean-Marc has 30 years of experience in the broader pharmaceutical industry... – including biologics and animal health. After 9 years in pharmaceutical marketing, he gained a Masters in Health Economics at Paris Dauphine University in 1995. Since then, Jean-Marc held various Local, Regional and Global positions encompassing pricing and reimbursement, HEOR, health policy, and government affairs (Novartis, Sanofi Pasteur Vaccines, Pfizer, Shire, Merck, Indivior). Jean-Marc brings experience gained over a vast number of pricing and market access challenges ranging from identifying value for early R&D projects, to protecting products from price erosion during late-stage commercialisation.
Read more

Max Rex

Before starting his career, Max attended Imperial College London, where he completed both an undergraduate degree in Biochemistry and an MRes in Molecular and Cellular Biosciences. His research spanned many topics and culminated in the identification of novel anti-malarial transmission blocking vaccine targets. Since university, Max has spent four years working in medical consulting, helping companies develop pricing and market access strategies for orphan drugs and gene therapies. In this time, he has gained experience across a range of areas including value communication, evidence mitigation strategies and value-based pricing. At Inbeeo, he aims to continue developing innovative and tailored solutions for clients across a range of therapeutic areas.
Read more

Michelle James

Michelle began her career in the Biomedical Sciences field, leading her to pursue a Phd in Clinical and Translational Research at Newcastle University. It was here where she developed a keen interest in product commercialisation and strategy from 'benchside to bedside' within the pharmaceutical industry, moving in 2018 into the healthcare insights environment. Over the past 2 years Michelle has applied her research skills to work across a range of projects from payer/stakeholder insights and price sensitivity testing to disease and competitor analyses, across a number of therapeutic areas, including: metabolic and autoimmune disease, oncology and neurology. Upon joining the Inbeeo team in 2020, she now looks to develop her healthcare consulting skills and further her knowledge in market access.
Read more

Erin Haney

Prior to joining Inbeeo, Erin worked in health economics and outcomes (HEOR) research consulting where she assisted clients in developing and executing strategic HEOR plans to demonstrate product value. Erin worked on multiple aspects of HEOR, including economic modelling, systematic and targeted literature reviews, value dossiers, and manuscripts for publication. Her experience spans a variety of disease areas, including oncology, autoimmune diseases, and rare diseases. Previously, Erin gained experience working in medical communications consulting and in a research setting where the goal of the research was to maximize the resilience of vulnerable older adults.   Erin holds an MPH specializing in Health Services and Systems (with distinction) from Imperial College London and an Honours B.Sc. degree in Life Sciences from McMaster University in Canada
Read more

Simon Doulé

Simon holds a master's degree in Public Affairs from Sciences Po Paris, which he obtained in parallel with his Doctorate in Pharmaceutical Sciences from the University of Paris. During his double curriculum, he worked in strategy consulting and in the pharmaceutical industry, familiarizing himself with drugs productivity chains. After graduating with a master's degree in health economics from Paris Dauphine, he held a position in the medico-economics department at Roche, developing an interest in the strategic valuation of health products. He hopes to use and expand his skills to help clients find the right price for their products in a sustained context of medical innovations.

Minh Kei (John) Lee

John graduated from University College London (UCL) with a BSc in Biotechnology. Whilst carrying out his studies, John undertook projects across multidisciplinary domains including biosciences, biochemical engineering and drug commercialization. He also had experience working in a life science venture capital firm in Hong Kong, which provided him with an understanding of the pharmaceutical and biotechnology industries from a business standpoint. Using his skillsets acquired thus far, he now looks to further develop his expertise in market access, pricing & reimbursement and deliver integrated market access solutions.

Konstantina Malliou-Najjar

Konstantina recently graduated (with distinction) with an MSc in International Health Management at Imperial Business College London. During this time, Konstantina undertook projects in the consulting sector, performed research on scientific topics and developed market entry strategies and business plans during different academic modules. Prior to this, she undertook a BSc in Biology in National and Kapodistrian University of Athens (NKUA), during which time Konstantina was specialised in the clinical analysis of bladder cancer.

Tania Savant

Tania recently graduated with distinction with a MSc in Clinical Neuroscience from University College London. The primary focus of her research was the development of novel gene therapy tools for the treatment of rare neurological disorders. During her studies, Tania gained experience in medical writing and consulting, with a focus on delivering publications for a wide range of disease areas, from neurology to oncology. Additionally, Tania holds a BSc in Neuroscience from University of St Andrews. Tania continues to expand her consulting skills and gain knowledge and insights in pricing and market access.

Sarah Kassenaar

Sarah began her career working in stem cell biology research, first in an academic lab exploring gene therapy and regenerative medicines for hearing loss and severe genetic diseases and gene therapies for haematological disorders, in particular sickle cell disease. It was at bluebird bio where she became interested in the commercial and market access areas of the industry, which led her to pursue a Master of Business Administration at the University of Cambridge. She also holds a Bachelor of Science (Honours) in Biological Sciences from the University of Guelph, and a graduate certificate in Biotechnology Management from the Harvard Extension School.

Sara Cueva Oemer

Before joining Inbeeo, Sara worked as an Analyst in Market Intelligence and Strategy at the Springer Nature Group, where she supported business strategic decision-making. Sara has an MA (Hons) in Psychology from the University of Edinburgh, where she conducted research on cognitive neuroscience. Alongside this, she worked on research related to consumer behaviour and prosociality with the University of Michigan and the University of Chicago. She then completed an MSc Public Health (with merit) at the London School of Hygiene and Tropical Medicine.

Yigit Ergin

Yigit graduated from University College London (UCL) with a First-Class Bachelor’s Degree in Biomedical Sciences, as well as an MSc in Drug Discovery and Pharmaceutical Management (with Distinction). During his Master’s, Yigit delivered projects spanning the whole pharmaceutical value chain, such as developing a clinical strategy for a new indication of a marketed drug and evaluating the implications of this strategy from a regulatory and market access standpoint. In addition to his studies, Yigit undertook industry experience at Silicon Valley-based biotech start-up Cantabio, where he supported the commercial development of multiple pipeline projects for the treatment of cancer and neurodegenerative diseases. Yigit now looks to further develop his expertise in pharmaceutical commercialisation by delivering critical pricing strategies and market access solutions. 

Valentina Matas

Operations lead with dual law and finance background and wide experience in project management and strategic planning. Valentina's main area of expertise is process design, digitalisation and adoption if scalable processes.

Asset 10

Connect to our experts

Have a question? Want to connect to one of our experts? Have an interesting pricing, reimbursement or Market Access challenge? Then please do get in touch – we would love to hear from you!
Have a question? Want to connect to one of our experts? Have an interesting pricing, reimbursement or Market Access challenge? Then please do get in touch – we would love to hear from you!

Tell us about you or your business,
we will get back to you